LAVA Therapeutics NV
NASDAQ:LVTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
LAVA Therapeutics NV
Income from Continuing Operations
LAVA Therapeutics NV
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Income from Continuing Operations
-$25.1m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Income from Continuing Operations
$2.5m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Income from Continuing Operations
-€42.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-7%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Income from Continuing Operations
-$199m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
argenx SE
XBRU:ARGX
|
Income from Continuing Operations
$1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
Income from Continuing Operations
-$381m
|
CAGR 3-Years
-82%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-31%
|
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
See Also
What is LAVA Therapeutics NV's Income from Continuing Operations?
Income from Continuing Operations
-25.1m
USD
Based on the financial report for Dec 31, 2024, LAVA Therapeutics NV's Income from Continuing Operations amounts to -25.1m USD.
What is LAVA Therapeutics NV's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-21%
Over the last year, the Income from Continuing Operations growth was 40%. The average annual Income from Continuing Operations growth rates for LAVA Therapeutics NV have been 18% over the past three years , -21% over the past five years .
